GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexicon Pharmaceuticals Inc (STU:LX31) » Definitions » Gross-Profit-to-Asset %

Lexicon Pharmaceuticals (STU:LX31) Gross-Profit-to-Asset % : 1.36% (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Lexicon Pharmaceuticals Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Lexicon Pharmaceuticals's annualized Gross Profit for the quarter that ended in Mar. 2024 was €4.04 Mil. Lexicon Pharmaceuticals's average Total Assets over the quarter that ended in Mar. 2024 was €297.11 Mil. Therefore, Lexicon Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 1.36%.


Lexicon Pharmaceuticals Gross-Profit-to-Asset % Historical Data

The historical data trend for Lexicon Pharmaceuticals's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexicon Pharmaceuticals Gross-Profit-to-Asset % Chart

Lexicon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 91.72 6.68 0.18 0.09 0.52

Lexicon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.51 0.21 0.99 1.36

Competitive Comparison of Lexicon Pharmaceuticals's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Lexicon Pharmaceuticals's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexicon Pharmaceuticals's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexicon Pharmaceuticals's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Lexicon Pharmaceuticals's Gross-Profit-to-Asset % falls into.



Lexicon Pharmaceuticals Gross-Profit-to-Asset % Calculation

Lexicon Pharmaceuticals's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=1.026/( (183.418+210.386)/ 2 )
=1.026/196.902
=0.52 %

Lexicon Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=4.044/( (210.386+383.841)/ 2 )
=4.044/297.1135
=1.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Lexicon Pharmaceuticals Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Lexicon Pharmaceuticals's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexicon Pharmaceuticals (STU:LX31) Business Description

Traded in Other Exchanges
Address
2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Lexicon Pharmaceuticals (STU:LX31) Headlines

No Headlines